On June 25, 2026, Haemonetics Corp (HAE) shares rose 6.5% today, bringing the current price to $77.6

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

Analysts upgraded HAE, VIK, and TXN, and raised price targets. Check out other analysts' views o

B of A Securities analyst Craig Bijou upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and rai

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price

FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consens

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innova

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the p

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.31 per share which beat the analyst consens

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")),

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential m

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel cl

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the pri

JP Morgan analyst Rohin Patel maintains Haemonetics (NYSE:HAE) with a Neutral and raises the pric

Citigroup analyst Joanne Wuensch downgrades Haemonetics (NYSE:HAE) from Buy to Neutral and raises

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Needham analyst Mike Matson maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly e

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67

  During Thursday's session, 108 stocks hit new 52-week highs.

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quar

Upgrades